Back to News
Market Impact: 0.25
Arrowhead Reports Positive Phase 1/2a Data For Alzheimer's Candidate ARO-MAPT
Source: Nasdaq
Healthcare & Biotech
Arrowhead Pharmaceuticals reported positive interim results from an ongoing Phase 1/2a study of ARO-MAPT, its investigational RNAi therapeutic for Alzheimer's disease and other tauopathies. The announcement provides no numerical efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
ARWR0.70
More News
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD
- Top biotechnology stock pick from Guggenheim
- Liquidia shares surge 25% as settlement ends United Therapeutics litigation
- Needham raises Starling Oncology stock price target on growth outlook
- Why is Olympus stock plunging today?